The DOI matches its Crossref record; 316 of the 316 references it cites were found in a registry or an index.
Modulating Glycolysis to Improve Cancer Therapy
Open accessAbstract
Cancer cells undergo metabolic reprogramming and switch to a ‘glycolysis-dominant’ metabolic profile to promote their survival and meet their requirements for energy and macromolecules. This phenomenon, also known as the ‘Warburg effect,’ provides a survival advantage to the cancer cells and make the tumor environment more pro-cancerous. Additionally, the increased glycolytic dependence also promotes chemo/radio resistance. A similar switch to a glycolytic metabolic profile is also shown by the immune cells in the tumor microenvironment, inducing a competition between the cancer cells and the tumor-infiltrating cells over nutrients. Several recent studies have shown that targeting the enhanced glycolysis in cancer cells is a promising strategy to make them more susceptible to treatment with other conventional treatment modalities, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, and photodynamic therapy. Although several targeting strategies have been developed and several of them are in different stages of pre-clinical and clinical evaluation, there is still a lack of effective strategies to specifically target cancer cell glycolysis to improve treatment efficacy. Herein, we have reviewed our current understanding of the role of metabolic reprogramming in cancer cells and how targeting this phenomenon could be a potential strategy to improve the efficacy of conventional cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–316 of 316
Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells
Previte, D. M., Martins, C. P., O’Connor, E. C., Marré, M. L., Coudriet, G. M., Beck, N. W., Menk, A. V., Wright, R. H., Tse, H. M., Delgoffe, G. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.004 · Cited by 84
GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress
González-Menéndez, P., Hevia, D., Alonso-Arias, R., Álvarez-Artime, A., Rodriguez-Garcia, A., Kinet, S., Gonzalez-Pola, I., Taylor, N., Mayo, J., & Sainz, R. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.017 · Cited by 82
Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer
Sawayama, H., Ogata, Y., Ishimoto, T., Mima, K., Hiyoshi, Y., Iwatsuki, M., Baba, Y., Miyamoto, Y., Yoshida, N., & Baba, H. (2019) · Cancer Science · doi:10.1111/cas.13995 · Cited by 82
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors
Gao, Y., Zhang, T., Terai, H., Ficarro, S. B., Kwiatkowski, N. P., Hao, M.-F., Sharma, B., Christensen, C. L., Chipumuro, E., Wong, K., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.11.007 · Cited by 80
Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes
Martins, C. P., New, L. A., O’Connor, E. C., Previte, D. M., Cargill, K. R., Tse, I., Sims‐Lucas, S., & Piganelli, J. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669456 · Cited by 78
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 78
Meng, M.-B., Wang, H.-H., Guo, W.-H., Wu, Z.-Q., Zeng, X.-L., Zaorsky, N. G., Shi, H., Qian, D., Niu, Z.-M., Jiang, B., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.016 · Cited by 77
Altered glycolysis results in drug‑resistant in clinical tumor therapy (Review)
Peng, J., Cui, Y., Xu, S., Wu, X., Huang, Y., Zhou, W., Wang, S., Fu, Z., & Xie, H. (2021) · Oncology Letters · doi:10.3892/ol.2021.12630 · Cited by 77
Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.
Ganapathy‐Kanniappan, S., Kunjithapatham, R., & Geschwind, J.-F. H. (2013) · PubMed · Cited by 76
González-Menéndez, P., Hevia, D., Mayo, J., & Sainz, R. (2018) · International Journal of Cancer · doi:10.1002/ijc.31165 · Cited by 76
Shen, L., Xiao, Y., Zhang, C., Li, S., Teng, X., Cui, L., Liu, T., Wu, N., & Lu, Z. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215710 · Cited by 76
Zhan, P., Zhao, S., Yan, H., Yin, C., Xiao, Y., Wang, Y., Ni, R., Chen, W., Wei, G., & Zhang, P. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22603 · Cited by 75
Xu, R., Wu, M., Liu, S., Shang, W., Li, R., Xu, J., Huang, L., & Wang, F. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03272-5 · Cited by 73
Liu, Y., Yan, X. S., Chen, J., Zhan, Q., Hua, Y., Xu, S., Li, Z., Wang, Z., Dong, Y., Zuo, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012228118 · Cited by 72
Oxamate targeting aggressive cancers with special emphasis to brain tumors
Altinoz, M. A., & Özpınar, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112686 · Cited by 72
Zhu, H., Wu, J., Zhang, W., Luo, H., Shen, Z., Cheng, H., & Zhu, X. (2016) · Scientific Reports · doi:10.1038/srep30788 · Cited by 71
Le, T. M., Poddar, S., Capri, J. R., Abt, E. R., Kim, W., Liu, W., Uong, N. T., Cheng, C., Braas, D., Nikanjam, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00221-3 · Cited by 71
A “Valve‐Closing” Starvation Strategy for Amplification of Tumor‐Specific Chemotherapy
Li, X., Jiang, C., Wang, Q., Yang, S., Cao, Y., Hao, J., Niu, D., Chen, Y., Han, B., Jia, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202104671 · Cited by 70
Kooshki, L., Mahdavi, P., Fakhri, S., Akkol, E. K., & Khan, H. Z. (2021) · BioFactors · doi:10.1002/biof.1799 · Cited by 69
Chung, Y. M., Khan, P. P., Wang, H., Tsai, W.-B., Qiao, Y., Yu, B., Larrick, J. W., & Hu, M. C. ‐. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002772 · Cited by 68
Icard, P., Simula, L., Fournel, L., Leroy, K., Mansuet‐Lupo, A., Damotte, D., Charpentier, M.-C., Durdux, C., Loi, M., Schussler, O., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100852 · Cited by 68
Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway
Yoshioka, E., Chelakkot, V. S., Licursi, M., Rutihinda, S. G., Som, J., Derwish, L., King, J. J., Pongnopparat, T., Mearow, K. M., Larijani, M., et al. (2018) · Theranostics · doi:10.7150/thno.22641 · Cited by 66
Self-citationSaulle, E., Spinello, I., Quaranta, M. T., Pasquini, L., Pelosi, E., Iorio, E., Castelli, G., Chirico, M., Pisanu, M. E., Ottone, T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621458 · Cited by 66
Papadaki, C., Sfakianaki, M., Lagoudaki, E. D., Giagkas, G., Ioannidis, G., Trypaki, M., Tsakalaki, E., Voutsina, A., Koutsopoulos, A. V., Mavroudis, D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.492 · Cited by 65
Linking Cancer Metabolism to DNA Repair and Accelerated Senescence
Efimova, E. V., Takahashi, S., Shamsi, N. A., Wu, D., Labay, E., Ulanovskaya, O. A., Weichselbaum, R. R., Kozmin, S. A., & Kron, S. J. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0263 · Cited by 65
Martinez‐Balibrea, E., Plasencia, C., Ginés, A., Martínez‐Cardús, A., Musulén, E., Aguilera, R., Manzano, J. L., Neamati, N., & Abad, A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0882 · Cited by 63
Golding, J. P., Wardhaugh, T., Patrick, L., Turner, M., Phillips, J. B., Bruce, J. I., & Kimani, S. G. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.391 · Cited by 63
Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis
Zhu, H., Luo, H., Zhu, X., Hu, X., Zheng, L., & Zhu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13703 · Cited by 63
Sabharwal, S. S., Rosen, D. B., Grein, J., Tedesco, D., Joyce-Shaikh, B., Ueda, R., Semana, M., Bauer, M., Bang, K., Stevenson, C., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0632 · Cited by 61
Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
Chen, S., Zhou, X., Yang, X., Li, W., Li, S., Hu, Z., Chen, L., Shi, R., Liu, J., Chen, G., et al. (2021) · Biomolecules · doi:10.3390/biom11091373 · Cited by 61
Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma
Wicks, R. T., Azadi, J. R., Mangraviti, A., Zhang, I., Hwang, L. S., Joshi, A. D., Bow, H. C., Hütt-Cabezas, M., Martin, K. L., Rudek, M. A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou143 · Cited by 60
Chen, L., Wu, Q., Xu, X., Yang, C., You, J., Chen, F., & Zeng, Y. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112414 · Cited by 60
Cengel, K. A., Simone, C. B., & GLATSTEIN, E. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0927 · Cited by 59
Glucose Metabolism in Cancer: The Saga of Pyruvate Kinase Continues
Allen, A. E., & Locasale, J. W. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.008 · Cited by 59
Halford, S. E. R., Jones, P. S., Wedge, S. R., Hirschberg, S., KATUGAMPOLA, S. D., Veal, G. J., Payne, G. S., Bacon, C. M., Potter, S., Griffin, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2516 · Cited by 59
Ahn, K. J., Hwang, H. S., Park, J. H., Bang, S.-H., Kang, W. J., Yun, M., & Lee, J. D. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060780 · Cited by 58
Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer
Pashaei-Asl, F., Pashaei‐Asl, R., Khodadadi, K., Akbarzadeh, A., Ebrahimie, E., & Pashaiasl, M. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1374281 · Cited by 58
Yan, S., Zhou, N. Q., Zhang, D., Zhang, K., Zheng, W., Bao, Y., & Yang, W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215415 · Cited by 58
Mandili, G., Curcio, C., Bulfamante, S., Follia, L., Ferrero, G., Mazza, E., Principe, M., Cordero, F., Satolli, M. A., Spadi, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001071 · Cited by 58
Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux
Jones, B. C., Pohlmann, P. R., Clarke, R. C., & Sengupta, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10027-5 · Cited by 57
Lee, C., & Choi, J. (2010) · Pharmacology · doi:10.1159/000312690 · Cited by 56
Noble, R. A., Thomas, H. D., Zhao, Y., Herendi, L., Howarth, R., Dragoni, I., Keun, H. C., Vellano, C. P., Marszalek, J. R., & Wedge, S. R. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01848-w · Cited by 55
Dietary Iron Controls Circadian Hepatic Glucose Metabolism Through Heme Synthesis
Simcox, J., Mitchell, T. C., Gao, Y. M., Just, S. F., Cooksey, R. C., Cox, J. E., Ajioka, R. S., Jones, D., Lee, S.-H., King, D., et al. (2014) · Diabetes · doi:10.2337/db14-0646 · Cited by 54
Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin
Chen, Q., Meng, Y.-Q., Xu, X.-F., & Gu, J. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000529 · Cited by 54
Yang, L., Lv, F., Liu, F., Guo, X., Fan, Y., Gu, F., Gu, J., & Fu, L. (2015) · Journal of Cancer · doi:10.7150/jca.12719 · Cited by 53
Recent advances in CAR-T cells therapy for colorectal cancer
Qin, X., Wu, F., Chen, C., & Li, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904137 · Cited by 53
Tsurutani, N., Mittal, P., Rose, M. S., Ngoi, S. M., Svedova, J., Ménoret, A., Treadway, F. B., Laubenbacher, R., Suarez-Ramirez, J. E., Cauley, L. S., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501217 · Cited by 52
Association of TIM-3 expression with glucose metabolism in Jurkat T cells
Lee, M. J., Yun, S. J., Lee, B., Jeong, E., Yoon, G., Kim, K. H., & Park, S. (2020) · BMC Immunology · doi:10.1186/s12865-020-00377-6 · Cited by 51
Lu, R., Jiang, M., Chen, Z., Xu, X., Hu, H., Zhao, X., Gao, X., & Guo, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074853 · Cited by 50
Wu, J., Hu, L., Chen, M., Cao, W., Chen, H., & He, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106508 · Cited by 49
Increased lactate dehydrogenase activity is dispensable in squamous carcinoma cells of origin
Flores, A., Sandoval-Gonzalez, S., Takahashi, R., Krall, A. S., Sathe, L., Wei, L., Radu, C. G., Joly, J. H., Graham, N. A., Christofk, H. R., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07857-9 · Cited by 49
Increased glucose availability sensitizes pancreatic cancer to chemotherapy
Gohar, A. V., Hue, J. J., Abbas, A., Graor, H. J., Hajihassani, O., Zarei, M., Titomihelakis, G., Feczko, J., Rathore, M. G., Chełstowska, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38921-8 · Cited by 49
Kiesslich, T., Plaetzer, K., Oberdanner, C. B., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.11.073 · Cited by 48
Li, Y., Weng, H.-C., Hsu, J., Lin, S., Guh, J., & Hsu, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01311 · Cited by 48
Shan, Y., Ni, Q., Zhang, Q., Zhang, M., Wei, B., Cheng, L., Zhong, C., Wang, X., Wang, Q., Liu, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.014 · Cited by 47
Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion
Song, B.-S., Moon, J. S., Tian, J., Lee, H. Y., Sim, B. C., Kim, S., Kang, S., Kim, J. T., Nga, H. T., Benfeitas, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004337 · Cited by 47
Zhang, J. J., Xue, W., Xu, K. W., Liang, Y., Guo, Y., Xie, T., Tong, H., Zhou, B., Wang, S., Li, Q., et al. (2020) · Theranostics · doi:10.7150/thno.44427 · Cited by 46
Ambrosio, M. R., D’Esposito, V., Costa, V., Liguoro, D., Collina, F., Cantile, M., Prevete, N., Passaro, C., Mosca, G., Laurentiis, M. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22552 · Cited by 45
Shao, S., Zhao, L., An, G., Zhang, L., Jing, X., Luo, M., Li, W., Du, M., Ning, Q., Zhao, X., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000951rr · Cited by 45
Jancewicz, I., Szarkowska, J., Konopiński, R., Stachowiak, M., Swiatek, M., Błachnio, K., Kubala, S., Oksinska, P., Cwiek, P., Rusetska, N., et al. (2021) · Cancers · doi:10.3390/cancers13164148 · Cited by 44
Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines
Attia, Y. M., El-Abhar, H. S., Marzabani, M. M. A., & Shouman, S. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1850-4 · Cited by 43
Almouhanna, F., Blagojevic, B., Can, S., Ghanem, A., & Wölfl, S. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00239-8 · Cited by 43
Chen, M.-L., Yuan, T.-T. T., Chuang, C.-F., Huang, Y.-T., Chung, I., & Huang, W. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0285 · Cited by 43
Mostafavi, S., Zalpoor, H., & Hassan, Z. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00356-2 · Cited by 43
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
Franklin, D. A., Sharick, J. T., Ericsson, P. I. G., Sanchez, V. M., Dean, P. T., Opalenik, S. R., Cairo, S., Judde, J., Lewis, M. T., Chang, J. C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134290 · Cited by 42
Kaur, P., Nagar, S., Bhagwat, M., Uddin, M., Zhu, Y. B., Vancurova, I., & Vančura, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260400 · Cited by 42
Cui, Y., Nadiminty, N., Liu, C., Lou, W., Schwartz, C. T., & Gao, A. C. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0107 · Cited by 41
Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors
Reyes‐Castellanos, G., Hadi, N. A., & Carrier, A. (2022) · Cells · doi:10.3390/cells11030426 · Cited by 41
Relationship between metabolic reprogramming and drug resistance in breast cancer
Lv, L., Yang, S., Zhu, Y., Zhai, X., Li, S., Tao, X., & Dong, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942064 · Cited by 41
A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy
Wang, L., Qu, M., Huang, S., Fu, Y., Yang, L., He, S., Li, L., Zhang, Z., Lin, Q., & Zhang, L. (2018) · Nanoscale · doi:10.1039/c8nr03297a · Cited by 40
Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines
Nozhat, Z., Mohammadi‐Yeganeh, S., Azizi, F., Zarkesh, M., & Hedayati, M. (2018) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-018-0208-2 · Cited by 40
Jiang, Y., Siu, M. K. Y., Wang, J., Leung, T. H. Y., Chan, D. W., Cheung, A., Ngan, H., & Chan, K. K. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.748403 · Cited by 40
Liu, Y., Yan, H., Gu, H., Zhang, E., He, J., Cao, W., Qu, J., Xu, R., Cao, L., He, D., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2057837 · Cited by 40
Sun, X., Fan, T., Sun, G., Zhou, Y., Huang, Y., Zhang, N., Zhao, L., Zhong, R., & Peng, Y. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115029 · Cited by 40
Zhou, N., Liu, Q., Wang, X., He, L., Zhang, T., Zhou, H., Zhu, X., Zhou, T., Deng, G., & Qiu, C. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01074-6 · Cited by 40
Song, C. W., Kim, H., Cho, H., Kim, M., Paek, S.-H., Park, H. J., Griffin, R. J., Terezakis, S. A., & Cho, L. C. (2022) · Cancers · doi:10.3390/cancers14133273 · Cited by 38
Zheng, J., Wong, C. W., Liu, J., Luo, X., Zhou, W.-Y., Chen, Y., Luo, H., Zeng, Z.-L., Ren, C., Xie, X., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2079182 · Cited by 36
Chow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 35
Omar, E. M., Omran, G. A., Mustafa, M. F., & El-Khodary, N. M. (2022) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-022-00141-4 · Cited by 35
Xu, W., Yang, W.-N., Wu, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.593706 · Cited by 34
PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
Sfakianaki, M., Papadaki, C., Tzardi, M. N., Trypaki, M., Manolakou, S. D., Messaritakis, I., Saridaki, Z., Athanasakis, E., Mavroudis, D., Tsiaoussis, J., et al. (2020) · Cancers · doi:10.3390/cancers12082058 · Cited by 33
Robert, C., Lewis, K. D., Gutzmer, R., Stroyakovskiy, D., Gogas, H. J., Анатольевна, П. С., Pereira, R. P., Eigentler, T., Rutkowski, P. L., Демидов, Л. В., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.076 · Cited by 33
Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy
Lei, J., Yang, Y., Lu, Z., Pan, H., Fang, J., Jing, B., Chen, Y., & Yin, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115153 · Cited by 32
Weng, H.-C., Sung, C., Hsu, J., Leu, W., Guh, J., Kung, F., & Hsu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879748 · Cited by 31
Zhang, P., Yang, Y., Qian, K., Li, L., Zhang, C., Fu, X., Zhang, X., Chen, H., Liu, Q., Cao, S., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010759 · Cited by 30
Hara, T., Koda, A., Nozawa, N., Ota, U., Kondo, H., Nakagawa, H., Kamiya, A., Miyashita, K., Itoh, H., Nakajima, M., et al. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12048 · Cited by 29
The PFKFB3 Inhibitor AZ67 Inhibits Angiogenesis Independently of Glycolysis Inhibition
Veseli, B. E., Wielendaele, P. V., Delibegović, M., Martinet, W., & Meyer, G. R. Y. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115970 · Cited by 29
The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer
Curcio, C., Brugiapaglia, S., Bulfamante, S., Follia, L., Cappello, P., & Novelli, F. (2021) · Molecules · doi:10.3390/molecules26061642 · Cited by 28
Zuo, Q., Mogol, A. N., Liu, Y.-J., Casiano, A. S., Chien, C., Drnevich, J. M., Imir, O. B., Kulkoyluoglu‐Cotul, E., Park, N. H., Shapiro, D. J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0781 · Cited by 28
MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1α-FECH axes
Chelakkot, V. S., Liu, K., Yoshioka, E., Saha, S., Xu, D., Licursi, M., Dorward, A. M., & Hirasawa, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-79144-x · Cited by 27
Self-citationYuan, S., Qiao, T., Zhuang, X., Chen, W., Xing, N., & Zhang, Q. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.6.1312 · Cited by 26
Mascaraque, M., Gallego-Rentero, M., Morala, J. N., Portillo-Esnaola, M., Cuezva, J. M., González, S., Gilaberte, Y., & Juarranz, Á. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101496 · Cited by 26
Xing, B.-C., Wang, C., Ji, F., & Zhang, X. (2018) · Europe PMC (PubMed Central) · Cited by 25
Metabolic Dysregulation Controls Endocrine Therapy–Resistant Cancer Recurrence and Metastasis
Blundon, M. A., & Dasgupta, S. (2019) · Endocrinology · doi:10.1210/en.2019-00097 · Cited by 24
Li, J., Pan, J., Liu, Y., Luo, X.-H., Yang, C., Xiao, W.-F., Li, Q.-S., Yang, L., & Zhang, X. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11447 · Cited by 24
Enhanced Antitumor Activity of 3-Bromopyruvate in Combination with Rapamycin In Vivo and In Vitro
Zhang, Q., Pan, J., Lubet, R. A., Komas, S. M., Kalyanaraman, B., Wang, Y., & You, M. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0142 · Cited by 23
Chao, R., Nishida, M., Yamashita, N., Tokumasu, M., Zhao, W., Kudo, I., & Udono, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864225 · Cited by 23
Yang, X., Palasuberniam, P., Myers, K. A., Wang, C., & Chen, B. (2016) · Oncotarget · doi:10.18632/oncotarget.11058 · Cited by 22
Feng, X., Zhang, Y., Wang, P., Liu, Q., & Wang, X. (2014) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00288a · Cited by 21
Santana‐Rivera, Y., Rabelo-Fernández, R. J., Quiñones‐Díaz, B. I., Grafals‐Ruiz, N., Santiago-Sánchez, G. S., Lozada-Delgado, E. L., Echevarría-Vargas, I. M., Apiz, J., Soto, D., Rosado, A., et al. (2020) · PubMed Central · Cited by 20
Development of PI3Kα inhibitors for tumor therapy
Jia, W., Luo, S., Guo, H. W., & Kong, D. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2132293 · Cited by 20
Telang, S., O’Neal, J., Tapolsky, G. H., Clem, B. F., Kerr, A., Imbert-Fernandez, Y., & Chesney, J. A. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-s1-p14 · Cited by 19
Sato, T., Yasuzawa, T., Uesaka, A., Izumi, Y., Kamiya, A., Tsuchiya, K., Kobayashi, Y., Kuwahata, M., & Kido, Y. (2014) · Nutrition Research · doi:10.1016/j.nutres.2014.04.013 · Cited by 19
Xie, R., Xu, T., Zhu, J., Wei, X., Zhu, W., Li, L., Wang, Y., Han, Y., Zhou, J., & Bai, Y. (2017) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2017.06.031 · Cited by 19
Scavengers Protection of Cells Against ALA-based Photodynamic Therapy-induced Damage
Perotti, C., Casas, A. G., & Batlle, A. M. D. C. (2002) · Lasers in Medical Science · doi:10.1007/s101030200033 · Cited by 18
Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells
Steifensand, F., Gallwas, J. K. S., Bauerschmitz, G. J., & Gründker, C. (2021) · Cells · doi:10.3390/cells10092398 · Cited by 18
Redman, R. A., Pohlmann, P. R., Kurman, M. R., Tapolsky, G. H., & Chesney, J. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.tps494 · Cited by 16
Grigalavicius, M., Ezzatpanah, S., Papakyriakou, A., Raabe, T. T. H., Yannakopoulou, K., & Theodossiou, T. A. (2022) · Cancers · doi:10.3390/cancers14164003 · Cited by 16
Al-Karakooly, Z., Al-Anbaky, Q. A., Kannan, K., & Ali, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206182 · Cited by 15
3-Bromopyruvate kills cancer cells in animals
Nelson, K. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00867-7 · Cited by 13
Gan, L., Ren, Y., Lu, J., Ma, J., Shen, X., & Zhuang, Z. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s273108 · Cited by 13
Zhong, G., Li, Q., Luo, Y., Liu, Y., Liu, D., Ли, Б., & Wang, T. (2022) · Journal of Oncology · doi:10.1155/2022/8943643 · Cited by 11
Song, K., Rajasekaran, N., Chelakkot, C., Lee, H. S., Paek, S., Yang, H., Jia, L., Park, H. G., Son, W. S., Kim, Y., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14101060 · Cited by 10
Self-citationIcard, P., Teboul, B., & Baze, P. E. (2017) · Anticancer Research · doi:10.21873/anticanres.12069 · Cited by 9
Increased glucose availability sensitizes pancreatic cancer to chemotherapyPreprint
Gohar, A. V., Hue, J. J., Graor, H. J., Abbas, A., Zarei, M., Hajihassani, O., Titomihelakis, G., Feczko, J., Rathore, M. G., Wang, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.29.490090 · Cited by 7
Liu, Y., Zhang, Y., Mao, X., Qi, Q., Zhu, M., Zhang, C., Pan, X., & Ling, Y. (2017) · Biomedical Reports · doi:10.3892/br.2017.1008 · Cited by 6
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Keoh, L. Q., Chiu, C.-F., & Ramasamy, T. S. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10956-y · Cited by 66
The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40
Aati, S., Farouk, H. O., Elkarmalawy, M. H., Aati, H. Y., Tolba, N. S., Hassan, H. M., Rateb, M. E., & Hamad, D. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111432 · Cited by 9
Metadata
- Authors
- Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-01-30
- Volume
- 24
- Issue
- 3
- Pages
- 2606
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4318478298
- Cited by
- 374
- References
- 316
- FWCI
- 36.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.